Aurinia Pharmaceuticals (AUPH)

• Market cap: $1.1B
• 1 day: -0.61%
• 5 days: -0.12%
• 1 month: 4.60%
• 3 months: 0.86%
• 6 months: -12.70%
• Year to date: -6.73%
• 1 year: 52.90%
• 5 years: -49.82%
• 10 years: 139.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]

86% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $7.71M

80% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 20

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

6% more funds holding

Funds holding: 197 [Q4 2024] → 209 (+12) [Q1 2025]

4.7% more ownership

Funds ownership: 40.37% [Q4 2024] → 45.07% (+4.7%) [Q1 2025]

4% less capital invested

Capital invested by funds: $519M [Q4 2024] → $498M (-$21.3M) [Q1 2025]